Recovery from FOLFOX chemotherapy-induced systemic and skeletal muscle metabolic dysfunction in mice

Authors

Jessica L. Halle, University of Tennessee Health Science Center
Brittany R. Counts, University of Tennessee Health Science Center
Hector G. Paez, University of Tennessee Health Science Center
Dryden R. Baumfalk, University of Florida
Quan Zhang, University of Tennessee Health Science Center
Junaith S. Mohamed, University of Tennessee Health Science Center
Evan S. Glazer, University of Tennessee Health Science Center
Melissa J. Puppa, University of Memphis
Ashley J. Smuder, University of Florida
Stephen E. Alway, University of Tennessee Health Science Center
James A. Carson, University of Tennessee Health Science Center

Abstract

FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) chemotherapy is used to treat colorectal cancer and can acutely induce metabolic dysfunction. However, the lasting effects on systemic and skeletal muscle metabolism after treatment cessation are poorly understood. Therefore, we investigated the acute and lasting effects of FOLFOX chemotherapy on systemic and skeletal muscle metabolism in mice. Direct effects of FOLFOX in cultured myotubes were also investigated. Male C57BL/6J mice completed four cycles (acute) of FOLFOX or PBS. Subsets were allowed to recover for 4 wk or 10 wk. Comprehensive Laboratory Animal Monitoring System (CLAMS) metabolic measurements were performed for 5 days before study endpoint. C2C12 myotubes were treated with FOLFOX for 24 hr. Acute FOLFOX attenuated body mass and body fat accretion independent of food intake or cage activity. Acute FOLFOX decreased blood glucose, oxygen consumption (V̇o2), carbon dioxide production (V̇co2), energy expenditure, and carbohydrate (CHO) oxidation. Deficits in V̇o2 and energy expenditure remained at 10 wk. CHO oxidation remained disrupted at 4 wk but returned to control levels after 10 wk. Acute FOLFOX reduced muscle COXIV enzyme activity, AMPK(T172), ULK1(S555), and LC3BII protein expression. Muscle LC3BII/I ratio was associated with altered CHO oxidation (r = 0.75, P = 0.03). In vitro, FOLFOX suppressed myotube AMPK(T172), ULK1(S555), and autophagy flux. Recovery for 4 wk normalized skeletal muscle AMPK and ULK1 phosphorylation. Our results provide evidence that FOLFOX disrupts systemic metabolism, which is not readily recoverable after treatment cessation. FOLFOX effects on skeletal muscle metabolic signaling did recover. Further investigations are warranted to prevent and treat FOLFOX-induced metabolic toxicities that negatively impact survival and life quality of patients with cancer.NEW & NOTEWORTHY The present study demonstrates that FOLFOX chemotherapy induces long-lasting deficits in systemic metabolism. Interestingly, FOLFOX modestly suppressed skeletal muscle AMPK and autophagy signaling in vivo and in vitro. The FOLFOX-induced suppression of muscle metabolic signaling recovered after treatment cessation, independent of systemic metabolic dysfunction. Future research should investigate if activating AMPK during treatment can prevent long-term toxicities to improve health and quality of life of patients with cancer and survivors.

Publication Title

American journal of physiology. Endocrinology and metabolism

Recommended Citation

Halle, J., Counts, B., Paez, H., Baumfalk, D., Zhang, Q., Mohamed, J., Glazer, E., Puppa, M., Smuder, A., Alway, S., & Carson, J. (2023). Recovery from FOLFOX chemotherapy-induced systemic and skeletal muscle metabolic dysfunction in mice. American journal of physiology. Endocrinology and metabolism, 325 (2), E132-E151. https://doi.org/10.1152/ajpendo.00096.2023